Utah Medical Products, Inc. (NASDAQ:UTMD - Get Free Report)'s share price passed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $67.97 and traded as low as $66.65. Utah Medical Products shares last traded at $66.80, with a volume of 32,585 shares.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded shares of Utah Medical Products from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 9th. One analyst has rated the stock with a Hold rating. According to MarketBeat, the stock has a consensus rating of "Hold".
View Our Latest Stock Analysis on UTMD
Utah Medical Products Price Performance
The firm has a market capitalization of $212.42 million, a PE ratio of 20.00 and a beta of 0.38. The firm has a fifty day moving average price of $72.97 and a 200 day moving average price of $67.97.
Utah Medical Products (NASDAQ:UTMD - Get Free Report) last posted its quarterly earnings data on Thursday, October 22nd. The medical instruments supplier reported $0.88 earnings per share (EPS) for the quarter. Utah Medical Products had a return on equity of 8.83% and a net margin of 30.48%. The firm had revenue of $8.62 million for the quarter.
Utah Medical Products Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, October 5th. Stockholders of record on Thursday, September 17th were issued a dividend of $0.31 per share. The ex-dividend date was Thursday, September 17th. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.9%. Utah Medical Products's payout ratio is currently 37.13%.
Insider Buying and Selling
In other news, CEO Kevin L. Cornwell acquired 1,000 shares of the firm's stock in a transaction that occurred on Thursday, October 29th. The stock was purchased at an average price of $66.75 per share, with a total value of $66,750.00. Following the purchase, the chief executive officer owned 189,472 shares of the company's stock, valued at approximately $12,647,256. This trade represents a 0.53% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 8.00% of the company's stock.
Hedge Funds Weigh In On Utah Medical Products
Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Utah Medical Products during the second quarter valued at $14,051,000. Rice Hall James & Associates LLC acquired a new position in Utah Medical Products in the 2nd quarter worth about $4,923,000. Bank of New York Mellon Corp acquired a new position in Utah Medical Products in the 2nd quarter worth about $2,363,000. Bard Associates Inc. purchased a new stake in shares of Utah Medical Products during the 2nd quarter worth about $1,279,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Utah Medical Products during the 2nd quarter worth about $544,000. 69.60% of the stock is currently owned by hedge funds and other institutional investors.
Utah Medical Products Company Profile
(
Get Free Report)
Utah Medical Products, Inc NASDAQ: UTMD develops, manufactures and distributes medical devices used primarily in hospital and clinical settings. The company focuses on specialized products for women's health, childbirth, neonatal care, electrosurgery, gastroenterology and related medical applications.
Its product portfolio includes fetal monitoring electrodes and catheters, intrauterine pressure monitoring devices, vacuum-assisted delivery systems, neonatal respiratory and care products, electrosurgical accessories, and other disposable and specialty medical instruments.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Utah Medical Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Utah Medical Products wasn't on the list.
While Utah Medical Products currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
